title: Pharmacological implications of lengthened in-utero exposure to nevirapine.
abstract: Given as a single dose to the mother during labour, nevirapine can protect the neonate from HIV-1 infection for up to 7 days. However, after maternal nevirapine therapy during pregnancy, neonatal plasma concentrations of nevirapine decline more rapidly, suggesting in-utero liver enzyme induction.
authors.forename: G P
authors.initials: GP
authors.lastname: Taylor
authors.forename: E G
authors.initials: EG
authors.lastname: Lyall
authors.forename: D
authors.initials: D
authors.lastname: Back
authors.forename: C
authors.initials: C
authors.lastname: Ward
authors.forename: G
authors.initials: G
authors.lastname: Tudor-Williams
mesh_terms: D019380:Anti-HIV Agents / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005260:Female; D005312:Fetal Blood; D015658:HIV Infections / Q000517:prevention & control*; D015497:HIV-1; D006207:Half-Life; D006801:Humans; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control; D007743:Labor, Obstetric; D008431:Maternal-Fetal Exchange; D008657:Metabolic Clearance Rate; D019829:Nevirapine / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D011247:Pregnancy
chemical_list: D019380:Anti-HIV Agents; D019829:Nevirapine